Management Team

Jarrett Gorlin

Mr. Gorlin serves as the Chief Executive Officer and a Director of the Company. He previously co-founded and served as President of Judicial Correction Services, Inc. which was named three consecutive years in a row as one of America’s fastest growing companies by Inc. Magazine. He served as President of Judicial Correction Services until successfully negotiating its sale to Correctional Healthcare Companies in 2011. He remained with Correctional Healthcare as its President until 2013.

Patrick Kullmann, M.B.A.

Mr. Kullmann served as senior director at Medtronic (NYSE:MDT) in their $2.3 billion Cardiovascular Division. In addition, he has served in marketing, market development and sales leadership positions at Boston Scientific (NYSE:BSX) Baxter (NYSE:BAX), Johnson & Johnson (NYSE:JNJ), and four start-up medical device companies – two of which had successful liquidity events with a combined valuation of $220M. He is also the author of the book “The Inventor’s Guide for Medical Technology” that is listed on Amazon. Mr. Kullmann has been a featured speaker and presenter globally on topics related to medical technology innovation.

Prior to joining Medovex, Mr. Wright was an audit senior at Ernst & Young within the Assurance Services division, where he had an opportunity to help manage audits of large ($2 billion to $10 billion annual revenue) publicly-traded companies. He also has experience auditing medium size ($2 million - $200 million annual revenue) privately-held companies in multiple industries with other accounting firms.

Prior to his career in public accounting, Mr. Wright worked as a trading analyst in the retirement trust services department at Reliance Trust Company, managing the institutional trading desk to settle mutual fund transactions with the National Securities Clearing Corporation. Mr. Wright holds Master of Professional Accountancy and Bachelor of Business Administration degrees from the Georgia State University Robinson College of Business and is a member of the Georgia Society of Certified Public Accountants.

Dennis Moon

Dennis Moon has served in an Executive Management position in both public and privately held companies over the past 15 years, including positions as Chief Operations Officer of Roadie, Inc., a mobile device and technology company; and Chief Operations Officer for Judicial Correction Services (JCS), where he assisted in the sale of the company to a private equity fund and remained COO of the JCS Division for Correctional Healthcare Companies. As COO, his responsibilities included supervising the day to day operations and maintenance of over 50,000 monthly clients, over 200 City, County, and State Contracts, 70 physical office locations, over 400 employees and over 1.8 million financial transactions per year. Prior to his career in Executive Management he served in the United States Army as an Intelligence Analyst and Combat Engineer with TS/SCI Clearance. Dennis holds a bachelor’s degree from the University of Central Florida.

Manfred Sablowski

Mr. Sablowski, a business professional with over 20 years of senior management experience in the medical technology industry, where he has been instrumental in managing and growing several highly successful companies. He has held several executive level positions such as General Manager at Valleylab/Pfizer, Europe; VP Sales and Marketing Dornier Medizin Technik, Europe; VP Sales and Marketing Bovie Medical-Worldwide. He also served as Board Member and Vice President/COO for Trod Medical, a successful venture backed start-up, in which he was involved from its inception. He is the principal of FMS MedTech Consulting, a consulting firm focusing on strategic planning for the international businesses in the medical industry (Europe and U.S.). Mr. Sablowski holds a bachelor of science, a diploma as chemical engineer and earned a MBA in Germany.

Jill Schweiger is a highly qualified and accomplished leader with a highly demonstrable track record of success in the areas of clinical studies and regulatory affairs. She has previously served as a Vice President and Director in at least six early stage medical device companies, as well as multinational med tech organizations such as Baxter Healthcare Corporation and Eli Lilly & Company.

Most recently, Schweiger served as Vice President, Clinical Studies & Regulatory Affairs for Flowonix Medical, Inc., a company focused on the development of implantable infusion pumps designed to deliver therapeutic drugs to relieve a variety of chronic disorders, such as spasticity and chronic intractable pain. While there, she was responsible for the development and execution of US and European regulatory and clinical strategies, that achieved PMA Approval in the US and CE Mark in Europe.

Prior to that, she was Vice President, Clinical & Regulatory Affairs at Angel Medical Systems, Inc., a company specializing in the development of an implantable cardiovascular monitoring system designed to detect ischemia which could be indicative of a heart attack. While there, she was responsible for developing and executing regulatory, clinical and quality strategies to support business and financing objectives and U.S. and international marketing applications.

Disclaimer

Medovex Corp. maintains this website as a service to the financial and internet communities. The site is intended to provide general information about the Company. It is not designed to be a source for making investment decisions. Medovex will make every reasonable effort to include accurate and current information on this website.

Except for the historical information contained herein, the information on the site may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company’s SEC filings.

Neither Medovex Corp nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user’s access, use, or liability to use the Company’s website, or any errors or omissions in the content of the Medovex Corp website.

Terms of Use
General

Medovex Corp. (“the Company”) has made a reasonable effort to provide accurate and current information on this website.

It is important to note that nothing on our website constitutes or should be construed as investment advice. Date and information presented is not furnished in connection with any sale, offer of sale, solicitation or an offer to buy a security.

Solicited Policy

Neither Medovex nor any of its employees accept or consider unsolicited ideas regarding marketing, technologies or product names. The goal is to avoid any potential misunderstandings when Medovex’s products or marketing strategies might appear similar to ideas submitted to the Company.

No Offer or Advice

This website does not constitute an offer to sell or a solicitation of an offer to buy any security referenced on this website. Medovex’s management never represents that a security, product or service discussed here, are suitable for any particular investor. We do not guarantee the accuracy, completeness or timeliness. We strongly advise that all individuals be aware of the risks involved in every business and stock. You can help protect yourself by being an educated investor by closely examining Company documents filed with the Securities and Exchange Commission (SEC) as well as all other documents that have been published.

Limitation of Liability – SEC Rule 606

Use of this website is at the viewer’s own risk. Its content including but not limited to: any graphics, links or other terms are provided on an “as is” basis without warranties or representations of any kind. The Company expressly disclaims any liability for any errors or omissions in the content included in this website. All changes (should and when they may occur) are effective immediately upon posting to this website.

Archived and Forward Information

Any reports filed with the SEC may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, some of which may be outside the Company’s control and may include economic, political and market fluctuations. Medovex undertakes no obligation to update or revise publicly any forward looking statement whether as a result of new information, future events or otherwise.

The Company strongly recommends readers carefully review all other documents and periodic reports filed by the Company with the SEC.

Medovex cannot and does not guarantee or warrant that files available for downloading (if any) through this site will be free of infection by software viruses or other harmful computer code, files or programs.